"We are excited to have completed administering first doses to all patients enrolled in our phase 2 Alzheimer's trial,” ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
Around 2 to 3 million people live with hepatitis C in the U.S. and 40% of those people (roughly 800,000) were not even aware ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback